

Initial opioid prescription compliant with CDC recommendations (MUC2018-106)

NQF MAP Clinicians Workgroup meeting
December 12, 2018

Darshak Sanghavi, MD, Chief Medical Officer and SVP Translation, OptumLabs
Stephan Dunning, MBA, Senior Program Director, Measure Development, OptumLabs



What is the measure?

What percentage of new opioid prescriptions are compliant with all 5 CDC guidelines criteria? Higher is better on this measure.

Numerator

Initial opioid prescription is:

1. Prescribed while patient is not exposed to benzodiazepine
2. Not for methadone
3. For short acting formulation
4. For less than 50 MME/day
5. For a 7-day supply or less



Denominator

All new opioid prescriptions in the measurement year for individuals with:

- Continuous enrollment with medical and pharmacy coverage in the measurement year
- 12 months of continuous pharmacy coverage prior to earliest opioid claim in the measurement year

There is highly variable compliance with CDC prescribing guidelines across the U.S., CY 2017

Initial opioid prescribing compliance with CDC recommendations by U.S. county level (composite measure) — *blue means better performance*




*Calculated in Commercial and Medicare Advantage enrollees.


Why a composite measure?

CDC guideline violations also vary substantially by criteria, CY 2017


#1. Initial opioid prescription is prescribed while patient is not exposed to benzodiazepines, 2017



#4. Initial opioid prescription is for < 50 MME/day, 2017




#5. Initial opioid prescription is for ≤ 7 days' supply, 2017



*Calculated in Commercial and Medicare Advantage enrollees.

Why do we care?

CDC compliance dramatically reduces the risk of long-term opioid use



Medicare Advantage ACOs using the composite in a QI program have demonstrated improvement

